University College Dublin
Welcome,         Profile    Billing    Logout  
 20 Trials 
30 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mallon, Patrick
NCT03696160 / 2018-003481-13: The Late Presenter Treatment Optimisation Study

Completed
3
447
Europe
Biktarvy, Symtuza
NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals
HIV/AIDS
06/24
06/24
ORCHESTRA-4, NCT05222139: Monitoring COVID-19 Vaccination Response in Fragile Populations

Active, not recruiting
N/A
8894
Europe, RoW
COVID-19 vaccination
University of Bologna, Universita di Verona, Hospital Universitario Virgen Macarena, Azienda Ospedaliera di Padova, Azienda Ospedaliero-Universitaria di Parma, Azienda Ulss 2 Marca Trevigiana, University College Dublin, Luxembourg Institute of Health, ICONA Foundation, University Medical Center Groningen, University of Buenos Aires, PENTA Foundation, Universiteit Antwerpen, Institut National de la Santé Et de la Recherche Médicale, France, Helmholtz Zentrum München, CINECA consorzio universitario italiano, Charite University, Berlin, Germany, Centre de Recherche Médicale de Lambaréné
SARS CoV 2 Infection, Vaccination; Infection, Breakthrough Infection
07/23
11/24
Roux, Carel W Le
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
NCT04595968: Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus

Completed
N/A
267
Europe, US
Vestal DM Active device, Lifestyle modification, Vestal DM Sham device
Neurovalens Ltd., University College Dublin, CS Lifescience, Clinical Trial Mentors
Type 2 Diabetes
08/24
08/24
VOYAGER, NCT06710587: Does Use of the Voy Program Improve Weight Loss Percentage and Other Health Outcomes in a Population Already Taking GLP/GIP-1RA Medication?

Not yet recruiting
N/A
470
NA
Voy Program
Menwell Limited, Lindus Health
Obesity, Weight Loss
04/26
04/27
Smith, Cameron R
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/24
12/25
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Active, not recruiting
2
30
Europe, US
SPI-62 dose
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
12/24
12/25
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
LINC6, NCT05382156: Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Active, not recruiting
N/A
206
Europe, US
Osilodrostat, Isturisa
RECORDATI GROUP
Endogenous Cushing's Syndrome
06/27
08/27
Silverstein, Julie M
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/24
12/25
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
LINC6, NCT05382156: Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Active, not recruiting
N/A
206
Europe, US
Osilodrostat, Isturisa
RECORDATI GROUP
Endogenous Cushing's Syndrome
06/27
08/27
O'Sullivan, Aifric
SuHeGuide, NCT05253547: Dietary Intervention Study on Food Based Dietary Guidelines for Sustainable and Healthy Lifestyles

Completed
N/A
355
Europe
Healthy climate-friendly dietary guidelines, Healthy dietary guidelines
University College Dublin, Teagasc, University College Cork, Queen's University, Belfast
Dietary Habits, Healthy Diet, Healthy Nutrition, Personalized Nutrition
06/23
06/23
Rowell, Jennifer
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
Manessis, Anastasios
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared with Semaglutide in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin with or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Recruiting
3
320
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes
09/26
10/26
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed
3
692
Europe, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Type 1 Diabetes, Diabetes
05/24
05/24
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting
3
405
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes

Active, not recruiting
N/A
575
US
MiniMed™ 780G Insulin Pump system
Medtronic Diabetes
Type 2 Diabetes Treated with Insulin
01/25
02/25
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
NA-PAS, NCT04836546: Eversense® Non-adjunctive Use Post Approval Study

Recruiting
N/A
925
US
Blood glucose meter, Eversense CGM System
Senseonics, Inc.
Diabetes
03/26
03/26
Srinath, Reshmi
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
NCT04595968: Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus

Completed
N/A
267
Europe, US
Vestal DM Active device, Lifestyle modification, Vestal DM Sham device
Neurovalens Ltd., University College Dublin, CS Lifescience, Clinical Trial Mentors
Type 2 Diabetes
08/24
08/24
Menezes, Camilo
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
Mejia, Kimberyly Valle
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
Diocareza, Anna
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
Roa, Hector
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
Brennan, ssor Lorraine
No trials found

Download Options